On February 23, Ge Longhui (688687.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved total operating revenue of 1,412 billion yuan, an increase of 21.74% year on year; realized net profit attributable to owners of the parent company of 116 million yuan, an increase of 39.22% year on year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 122 million yuan, an increase of 123.88% year on year.
During the reporting period, with the gradual recovery of market demand, the company strengthened its marketing network layout and marketing system construction. While maintaining the market share of mature products, the hepatitis C market layout gradually took shape, the number of patients using medication continued to increase, and the overall sales scale increased significantly compared to the previous year.